Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC ACV Tripeptide TFA | 477.45 | 25 MG
ACV Tripeptide TFA is a tripeptide that serves as the initial dedicated intermediate in the biosynthetic pathway leading to penicillin and cephalosporin classes of β-lactam natural products in bacteria and fungi. It is nonribosomally synthesized by the ACV synthetase (ACVS) enzyme, encoded by the 11 kb *pchAB* gene, and can be used for the biosynthesis of β-lactam antibiotics. This tripeptide contains the unusual amino acid α-aminoadipic acid (α-AAA), along with L-cysteine and D-valine.
- Tripeptide
- Initial intermediate in β-lactam biosynthesis
- Synthesized by ACV synthetase (ACVS) enzyme
- Contains α-aminoadipic acid (α-AAA), L-cysteine, and D-valine
- Molecular weight: 477.45
- Formula: C16H26F3N3O8S
- Appearance: Solid
Medchemexpress LLC Mm-102 trifluoroacetate | 1883545-52-5 | 99.7% | 1 ML
MM-102 TFA is the trifluoroacetate salt of MM-102, a potent inhibitor of the WDR5/MLL protein-protein interaction, supplied as a ready-to-use 10 mM solution in DMSO for research applications.
- Potent WDR5/MLL interaction inhibitor (IC50 = 2.4 nM).
- Supplied as a 10 mM solution in DMSO, 1 mL volume.
- High purity listed at 99.68% (reported as 99.7%).
- Molecular weight 783.83 g·mol⁻1; formula C37H50F5N7O6.
- For research use only; not for human or clinical use.
Medchemexpress LLC Astax-35r TFA | 99.1% | 2392.86 | 5 MG
aStAx-35R TFA is a stapled peptide that antagonizes the nuclear form of β-catenin and inhibits Wnt signaling. It competitively inhibits the binding of β-catenin to TCF4 and selectively induces growth inhibition of Wnt-dependent cancer cells.
- Antagonizes nuclear form of β-catenin.
- Inhibits Wnt signaling.
- Competitively inhibits the binding of β-catenin to TCF4.
- Selectively induces growth inhibition of Wnt-dependent cancer cells.
Medchemexpress LLC Cyclo(RLsKDK) TFA | 99.7% | 841.88 | 1 MG
Cyclo(RLsKDK) TFA is a specific inhibitor of metalloproteinase ADAM8 with an IC50 value of 182 nM. It is utilized in research for inflammatory diseases and cancer studies.
- Specific inhibitor of metalloproteinase ADAM8 (IC50 182 nM).
- Promotes ADAM8 activation and CD23 shedding (IC50 120 nM and 182 nM).
- Increases activity of pro-ADAM8.
- Reduces tumor load and improves survival rates in pancreatic ductal adenocarcinoma (PDAC) mice models.
- Reduces sADAM8 content, pERK1/2 activation, and PDAC metastasis in vivo.
Chem-Impex International, Inc. Trifluoroacetic acid | 76-05-1 | MFCD00004169 | 100G
Trifluoroacetic acid, 76-05-1, MFCD00004169, 100G
Medchemexpress LLC Liraglutide TFA | 99.6% | 3751.20 | 5 MG
Liraglutide (TFA) is an agonist of the glucagon-like peptide 1 receptor (GLP-1). It can activate GLP-1, resulting in the release of insulin when glucose concentration is elevated. Additionally, Liraglutide (TFA) reduces glucagon secretion in a glucose-dependent manner and can be utilized in research concerning type 2 diabetes.
- Agonist of glucagon-like peptide 1 receptor (GLP-1)
- Activates GLP-1, which leads to insulin release in the presence of increased glucose concentration
- Reduces glucagon secretion in a glucose-dependent manner
- Can be studied in research on type 2 diabetes
Medchemexpress LLC Jbsnf-000028 Tfa | C13H14F3N3O2 | 1 ML
JBSNF-000028 TFA is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. It can reduce endogenous MNA levels in U2OS osteosarcoma cells, with an EC50 of 2.5 μM. This compound exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model and can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease.
- Orally active small molecule inhibitor of NNMT
- Reduces endogenous MNA levels in U2OS osteosarcoma cells
- Exhibits anti-obesity and anti-diabetic activities
- Useful for studying metabolic diseases like obesity, type 2 diabetes, and non-alcoholic fatty liver disease
Medchemexpress LLC 5A2-SC8 TFA | 1857341-90-2 | 98.6% | C93H173N5O20S5.xC2HF3O2 | 1 MG
5A2-SC8 TFA is an ionizable amino lipid utilized in lipid nanoparticles (LNPs), demonstrating significant potential for drug delivery with low in vivo toxicity. It facilitates the efficient delivery of small RNAs, such as siRNA and miRNA, specifically into tumor cells. This compound's LNPs can uniquely influence the delivery fate of RNA within the liver, thereby improving therapeutic outcomes in various cancer models.
- High delivery potential.
- Low in vivo toxicity.
- Enables efficient delivery of small RNAs (siRNA and miRNA) into tumor cells.
- Can alter therapeutic outcomes in cancer models by influencing RNA delivery in the liver.
Sigma Aldrich Fine Chemicals Biosciences TRIFLUOROACETIC ACID 100ML
NC3241523 TRIFLUOROACETIC ACID 100ML
Apexbio Technology LLC CTOP TFA 1mg
CTOP TFA is a small-molecule antagonist targeting the -opioid receptor (MOR) It is designed to selectively inhibit MOR thereby regulating opioid receptor-mediated neural signaling pathways CTOP TFA exerts its biological activity primarily through specific interaction with and inhibition of MOR in the central nervous system Based on these pharmacological properties CTOP TFA holds research potential in investigating pain perception analgesia tolerance dependence neurotransmitter release stress responses and emotional regulation